The Cerebellum· 2026Q1
Parkinsonism with Reduced Striatal Uptake on DAT-SPECT in a Patient Harboring a Novel KCND3 Variant
- 0citations
- Q1SCImago
- 2026year
Short summary
A patient with a novel KCND3 variant, associated with spinocerebellar ataxia, presented with parkinsonism and reduced striatal uptake on DAT-SPECT, a finding not previously reported in this condition.
AI-generated from the title and abstract; the full text is not read.
Key points
- A patient with a novel KCND3 missense variant, linked to SCA19/22, exhibited both cerebellar ataxia and parkinsonism.
- DAT-SPECT imaging showed reduced striatal uptake in this patient.
- This reduced striatal uptake is a novel finding in patients with SCA19/22-related phenotypes.
- Parkinsonian symptoms showed a partial, clinically observed response to dopaminergic therapy.
AI-generated from the title and abstract; the full text is not read.
Abstract
KCND3 encodes the voltage-gated potassium channel Kv4.3, and pathogenic variants in KCND3 are associated with spinocerebellar ataxia type 19/22 (SCA19/22) and related neurological phenotypes. Here, we report a Japanese patient harboring a novel KCND3 missense variant, classified as a variant of uncertain significance, who presented with a clinical phenotype compatible with SCA19/22, including slowly progressive cerebellar ataxia beginning in childhood, accompanied by asymmetric parkinsonism. Dopamine transporter single-photon emission computed tomography demonstrated reduced striatal uptake. Parkinsonian symptoms exhibited a partial response to dopaminergic therapy; however, the improvement was primarily based on clinical observation, with limited objective evidence supporting treatment efficacy. To our knowledge, abnormal dopamine transporter imaging has not been previously reported in patients with SCA19/22-related phenotypes. Although it was difficult to determine whether the parkinsonism was attributable to the KCND3 variant or to coexisting Lewy body disease, we reviewed the literature on parkinsonism associated with SCA19/22 and discussed the potential contributions of both pathologies in the present case.
The authors' abstract, as published at the source. The Cerebellum, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Cellular and Molecular Neuroscience
Cellular and Molecular NeuroscienceNeuroscience